Comparing Observation, Axillary Radiotherapy, and Completion Axillary Lymph Node Dissection for Management of Axilla in Breast Cancer in Patients with Positive Sentinel Nodes: A Systematic Review

• Published in: Annals of surgical oncology 2020-08, Vol.27 (8), p.2664-2676
• Main Authors: Castelo, Matthew, Hu, Shu Yang, Dossa, Fahima, Acuna, Sergio A., Scheer, Adena S.
• Format: Article
• Language: English
• Subjects: Axilla; Breast cancer; Breast Neoplasms - pathology; Breast Neoplasms - radiotherapy; Breast Neoplasms - surgery; Breast Oncology; Clinical trials; Female; Humans; Lymph Node Excision; Lymph nodes; Lymph Nodes - surgery; Lymphatic Metastasis; Lymphatic system; Lymphedema; Medicine; Medicine & Public Health; Morbidity; Oncology; Paresthesia; Patients; Radiation therapy; Randomized Controlled Trials as Topic; Sentinel Lymph Node - surgery; Sentinel Lymph Node Biopsy; Statistical analysis; Surgery; Surgical Oncology; Survival; Systematic review; Watchful Waiting
• ISSN: 1068-9265; 1534-4681
• DOI: 10.1245/s10434-020-08225-y

Purpose Several randomized controlled trials (RCTs) have investigated observation or axillary radiotherapy (ART) in place of completion axillary lymph node dissection (cALND) for management of positive sentinel nodes (SNs) in clinically node-negative women with breast cancer. The optimal treatment strategy for this population is not known. Methods MEDLINE, Embase, and EBM Reviews—NHS Economic Evaluation Database were searched from inception until July 2019. A systematic review and narrative summary was performed of RCTs comparing observation or ART versus cALND in clinically node-negative female breast cancer patients with positive SNs. The Cochrane risk of bias tool for RCTs was used to assess risk of bias. Outcomes of interest included overall survival (OS), disease-free survival (DFS), axillary recurrence, and axillary surgery-related morbidity. Results Three trials compared observation with cALND, and two trials compared ART with cALND. No studies blinded participants or personnel, and there was heterogeneity in inclusion criteria, study design, and follow-up. Neither observation nor ART resulted in statistically inferior 5- or 8-year OS or DFS compared with cALND. There was also no statistically significant increase in axillary recurrences associated with either approach. Four trials reported morbidity outcomes, and all showed cALND was associated with significantly more lymphedema, paresthesia, and shoulder dysfunction compared with observation or ART. Conclusions Women with clinically node-negative breast cancer and positive SNs can safely be managed without cALND.